Holen Sie sich die Stockscreener-App
0.9165
10.51%
0.0872
Handel nachbörslich:
.94
0.0235
+2.56%
Immunic Inc Aktie (IMUX) Neueste Nachrichten
What are the future prospects of Immunic Inc.July 2025 Intraday Action & Consistent Return Strategy Ideas - thegnnews.com
Immunic (IMUX) Q2 Loss Widens 25% - AOL.com
Momentum Screeners Rank Immunic Inc. in Top 5 TodayCapital Protection Trading Strategies Gain Interest - beatles.ru
H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data - Investing.com
H.C. Wainwright reiterates Buy rating on Immunic stock, citing positive MS data By Investing.com - Investing.com South Africa
Immunic, Inc. Advances Multiple Sclerosis Drug Trials - TipRanks
Immunic, Inc. shares rise 3.21% premarket after Novartis' positive Phase III trial results for ianalumab in Sjögren's disease. - AInvest
William Blair Maintains Immunic(IMUX.US) With Buy Rating - 富途牛牛
Is Immunic Inc. stock a value trapInvestment Timing Signals - mustnews.co.kr
Technical signs of recovery in Immunic Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
Will Immunic Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Intraday pattern recognizer results for Immunic Inc.Free Early Entry Tips With Low Risk Zone - Newser
Immunic reports promising Phase 2 data for lead drug candidate in progressive MSICYMI - Proactive financial news
Is a relief rally coming for Immunic Inc. holdersConservative Investment Setup and Risk Analysis - Newser
Immunic Advances Phase 3 Trials and Financial Health - The Globe and Mail
Immunic: Q2 Earnings Snapshot - Connecticut Post
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Malaysian Reserve
Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Small cap wrap: Immunic, Nextech3D.ai, EDM Resources, Alvopetro… - Proactive financial news
Immunic Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS - Proactive financial news
Immunic CEO Discusses Strong Q2 Progress in Vidofludimus Calcium Trials for MS Treatment - AInvest
Immunic advances MS drug program with Phase 3 trials fully enrolled - Proactive financial news
Immunic Q2 net loss widens, flags potential cash raise - AInvest
Biotech Immunic Q2 net loss widens, flags need to raise cash - MarketScreener
Immunic, Inc.: A High-Potential Biotech Play in the MS and GI Therapeutics Space - AInvest
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Ariva
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic, Inc. shares fall 1.43% after-hours as ImmunoPrecise Antibodies Ltd. reports earnings miss and auditor raises 'going concern' doubt. - AInvest
Immunic, Inc. shares fall 2.36% premarket after Sonnet BioTherapeutics' clinical trial data shows potential for SON-1010 in ovarian cancer. - AInvest
Immunic Inc. Stock Analysis and ForecastBreakout profit opportunities - Jammu Links News
When is Immunic Inc. stock expected to show significant growthMarket-crushing stock picks - Jammu Links News
How does Immunic Inc. compare to its industry peersMaximize gains with proven stock analysis - Jammu Links News
What is the dividend policy of Immunic Inc. stockMaximize returns with strategic portfolio planning - Jammu Links News
Should I hold or sell Immunic Inc. stock in 2025Invest confidently with real-time data analysis - Jammu Links News
What is the risk reward ratio of investing in Immunic Inc. stockSuperior profit margins - Jammu Links News
What are analysts’ price targets for Immunic Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News
What institutional investors are buying Immunic Inc. stockUnstoppable investment returns - Jammu Links News
What drives Immunic Inc. stock priceGain access to exclusive stock analysis - Jammu Links News
Is it the right time to buy Immunic Inc. stockProven strategies for superior portfolio growth - Jammu Links News
Is Immunic Inc. a growth stock or a value stockBuild wealth faster with consistent investment plans - Jammu Links News
Immunic, Inc. (NASDAQ:IMUX) Receives $7.50 Consensus Target Price from Brokerages - Defense World
Published on: 2025-08-03 05:26:52 - Jammu Links News
How volatile is Immunic Inc. stock compared to the marketTurbocharged investment results - Jammu Links News
How Immunic Inc. stock performs during market volatilityAccurate Forecast System with AI Support - Newser
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):